Autologous Immune Cell Therapy in Primary Hepatocellular Carcinoma Patients Following Resection and TACE Therapy (DC-TC)
Although liver resection, liver transplantation, a-interferon, Transarterial Chemo Embolization (TACE), percutaneous ethanol injection (PEI), Percutaneous microwave coagulation therapy (PMCT), Radiofrequency ablation (RFA) provide options to treat patients with HCC, the high recurrence rate of mid-late stage liver cancer still exists. The safety of autologous Immune Cell Therapy in Primary Hepatocellular Carcinoma (HCC) Patients Following Resection and TACE Therapy will be evaluated.
|Study Design:||Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Clinical Study of the Safety of Autologous Immune Cell Therapy in Primary Hepatocellular Carcinoma Patients Following Resection and TACE Therapy|
- Vital signs，physical examinations and adverse events [ Time Frame: one year ] [ Designated as safety issue: Yes ]The number of adverse events along with the results of vital signs measurements, physical examinations, and clinical laboratory tests will be used to determine the safety profile of DC-TC.
|Study Start Date:||December 2012|
|Estimated Primary Completion Date:||October 2013 (Final data collection date for primary outcome measure)|
The study is a single center,open label trial. To obtain safety information on toxicities and adverse events attributable to the subcutaneous injections of autologous dendritic cells incubated with irradiated autologous tumor stem cells and suspended in GM-CSF in patients with HCC.
|Contact: Xiaojin Wangfirstname.lastname@example.org|
|9585 Humin Road,Xuhui district||Recruiting|
|Shanghai, Shanghai, China, 200235|
|Contact: Xiaojin Wang email@example.com|
|Principal Investigator: Chengwei Chen|
|Sub-Investigator: Xiaojin Wang|
|Principal Investigator:||Chengwei Chen||Shanghai 85 Hospital|